Case Study 1 Abstract
This case study describes a 33-year-old female presenting with periodontitis and receiving treatment with Arestin. The patient reports receiving treatment for Hepatitis C, excessive weight, and having an implant since 2019. After completing assessments and developing a treatment plan based on periodontal charting and a radiograph statement, the patient was approved for treatment with Arestin at the distal site with a 5 mm pocket depth to reduce pocket depth. The patient’s periodontal status is classified as Periodontitis, Stage 1, Grade B. Arestin was administered in the distal site of the tooth on November 4, 2023. Reevaluation of the distal site of the tooth after treatment by Arestin revealed a reduction of pocket depth from 5 mm to 3 mm on February 3, 2024. The main goals of treatment with Arestin are reducing inflammation in the gingival tissue, bleeding, and pocket depth for maintaining stabilized oral health.
Case Study 2 Abstract
In the case of the 52-year-old patient, who presents with periodontitis and is receiving treatment with Arestin. Additionally, the patient has multiple dental concerns, including attrition, extrusion with a cleft, mobility, a unilateral click on the left side in TMJ, abfraction, overhang, broken enamel, and caries. After completing all assessments and developing a treatment plan for the patient based on periodontal examination, treatment with Arestin on-site with a 5 mm pocket depth was approved. The patient’s periodontal status is classified as Periodontitis, Stage 3, Grade B. Arestin was administered at the three sites of teeth on December 11, 2023. Re-evaluation of the three sites of teeth (3mm) after treatment by Arestin identified a reduction of pocket depth from 5 mm to 3 mm on February 6, 2024. The purpose of comprehensive treatment is to maintain oral health and prevent periodontal disease from progressing.
